Analysts take a look at Medtronic plc (NYSE:MDT) having this to say.

July 27, 2018 - By Jason Dias

Medtronic plc (NYSE:MDT) LogoInvestors sentiment increased to 1.08 in 2018 Q1. Its up 0.06, from 1.02 in 2017Q4. It is positive, as 80 investors sold Medtronic plc shares while 383 reduced holdings. 88 funds opened positions while 414 raised stakes. 1.04 billion shares or 0.00% more from 1.04 billion shares in 2017Q4 were reported.
Retirement Of Alabama invested in 0.39% or 982,431 shares. Boothbay Fund Mngmt Limited Liability Corporation holds 4,477 shares. America First Investment Ltd Liability holds 0.02% or 695 shares in its portfolio. Cap Research Glob Investors holds 16.86 million shares or 0.38% of its portfolio. Bbva Compass State Bank reported 0.41% of its portfolio in Medtronic plc (NYSE:MDT). Hemenway Trust Ltd Liability Company holds 9,173 shares. Sol Cap Management owns 5,661 shares. South Street Advisors Ltd Liability Com accumulated 112,384 shares. First Foundation Advsrs holds 1.64% in Medtronic plc (NYSE:MDT) or 366,835 shares. South Dakota Investment Council reported 628,447 shares or 1.15% of all its holdings. Hayek Kallen Invest Management holds 2,600 shares. Cohen Klingenstein Ltd Llc reported 29,300 shares. Moreover, Vanguard Inc has 0.38% invested in Medtronic plc (NYSE:MDT). Hl Serv Limited Liability Co has invested 0.03% of its portfolio in Medtronic plc (NYSE:MDT). Bb&T Securities, Virginia-based fund reported 399,843 shares.

Medtronic plc (NYSE:MDT) Ratings Coverage

Among 8 analysts covering Medtronic (NYSE:MDT), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Medtronic has $9800 highest and $88 lowest target. $93.86’s average target is 5.15% above currents $89.26 stock price. Medtronic had 12 analyst reports since February 5, 2018 according to SRatingsIntel. Needham maintained Medtronic plc (NYSE:MDT) on Wednesday, February 21 with “Buy” rating. Citigroup maintained it with “Buy” rating and $93 target in Thursday, February 22 report. Bank of America maintained the shares of MDT in report on Wednesday, June 6 with “Buy” rating. The firm earned “Market Perform” rating on Wednesday, June 6 by William Blair. The firm earned “Buy” rating on Thursday, May 24 by Bank of America. On Thursday, March 29 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The firm earned “Equal-Weight” rating on Monday, February 5 by Morgan Stanley. Needham maintained Medtronic plc (NYSE:MDT) rating on Thursday, May 24. Needham has “Buy” rating and $9700 target. Piper Jaffray initiated Medtronic plc (NYSE:MDT) on Friday, April 27 with “Buy” rating. As per Friday, May 25, the company rating was maintained by Morgan Stanley. Below is a list of Medtronic plc (NYSE:MDT) latest ratings and price target changes.

27/06/2018 Broker: Bernstein Rating: Market Perform New Target: $88 Initiates Coverage On
06/06/2018 Broker: Bank of America Rating: Buy New Target: $98.0000 Maintain
06/06/2018 Broker: William Blair Rating: Market Perform Reinitiate
31/05/2018 Broker: Raymond James Rating: Outperform New Target: $96 Initiates Coverage On
25/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $90 New Target: $95 Maintain
24/05/2018 Broker: Needham Rating: Buy New Target: $97.0000 Maintain
24/05/2018 Broker: Bank of America Rating: Buy New Target: $98.0000 Maintain
27/04/2018 Broker: Piper Jaffray Rating: Buy New Target: $90.0000 Initiate
29/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $95 New Target: $90 Maintain
22/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $100 New Target: $93 Maintain

The stock decreased 0.52% or $0.47 during the last trading session, reaching $89.26. About 3.88M shares traded. Medtronic plc (NYSE:MDT) has risen 0.84% since July 27, 2017 and is uptrending. It has underperformed by 11.73% the S&P500.

Medtronic plc manufactures and sells device medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company has market cap of $120.65 billion. The companyÂ’s Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It has a 39.32 P/E ratio. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases.

Medtronic plc (NYSE:MDT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.